HAEMOLYSIS BY URINARY ESCHERICHIA COLI
AND VIRULENCE IN MICE

J. F. VAN DEN BOSCH, P. POSTMA, J. DE GRAAFF* AND D. M. MACLAREN

Department of Medical Microbiology and *Department of Oral Microbiology, School of
Medicine, Free University, 1007 MC Amsterdam, The Netherlands

PLATE XVIII

SUMMARY. The influence of haemolysin production on virulence was studied in an experimental mouse model. Urinary strains of Escherichia coli can be divided into three virulence groups by determining their kinetics in the mouse kidney after intravenous injection. Virulent strains of groups II and III were more often haemolytic than avirulent group-I strains. Haemolytic virulent strains often caused haemoglobinuria in the mice, and killed the mice more rapidly than did non-haemolytic virulent strains. No relationship was found between α-haemolytic activity and virulence in wild-type haemolytic strains. When haemolysin production was reduced or eliminated by treatment with actinomycin-D or rifampicin, six out of seven group-II strains tested gave the same results as avirulent group-I strains. However, the kinetics in the mouse kidney of four haemolytic group-III strains tested was not changed after reduction or elimination of haemolysin production; only a small decrease in toxicity was observed. It is concluded that haemolysin production by E. coli is a decisive virulence factor in most of the mouse-nephropathogenic group-II strains, but not in the virulent group-III strains.

INTRODUCTION

Haemolysin production is a general phenomenon found in many strains of Escherichia coli. Four different haemolysins have been described (Jorgensen et al., 1976), and the most important types produced by E. coli are α and β haemolysins. The α haemolysin is a cell-free, filtrable protein, produced during log-phase growth by modification of a precursor molecule present in fresh meat and blood (Lovell and Rees, 1960; Smith, 1963; Snyder and Koch, 1966; Short and Kurtz, 1971; Zwadyk and Snyder, 1971; Rennie and Arbuthnott, 1974; Williams, 1979). The β haemolysin is cell associated; its activity cannot be dissociated from intact bacteria and appears to be closely associated with cell metabolism (Smith, 1963; Short and Kurtz, 1971). Several studies have indicated that haemolysis may be a virulence factor of E. coli and may play a role in the pathogenesis of urinary-tract infections. Dudgeon,
Wordley and Bawtree (1921, 1922) reported that haemolytic strains of *E. coli* were much commoner in urinary-tract infections in the male than in the female. Cooke and Ewins (1975) and Minshew *et al.* (1978a and b) found that strains of *E. coli* causing urinary-tract infections were haemolytic more commonly than faecal strains.

In a previous study we found differences in virulence between different strains of *E. coli* in a mouse model (van den Bosch, de Graaff and MacLaren, 1979). We were able to divide the strains into three virulence groups on the basis of the kinetics of the viable counts in the kidney and other organs after intravenous injection, and the measurement of LD50 values and killing times.

In the present study we have investigated the relationship between haemolysin production by *E. coli* and virulence in the experimental mouse model.

### MATERIALS AND METHODS

**Bacterial strains.** The 55 strains of *E. coli* used in this study were isolated from cases of urinary-tract infection either in general practice or in hospital patients, and were described previously (van den Bosch *et al.*, 1979, 1980a and c). Strains AD27 and AD27b were kindly supplied by Dr L. Emödy (University of Pécs, Hungary), and were originally numbered P673 and P673/1.

**Screening for haemolysis and assay of α-haemolytic activity.** Haemolysis was tested on washed-blood agar plates. Defibrinated sheep blood (Gibco, Glasgow) was washed three times in phosphate-buffered saline (PBS, pH 7-0) and added to Blood Agar Base No. 2 (Oxoid) to give a final concentration of 5% (v/v). After incubation overnight at 37°C, haemolysis was scored on a scale from − to +++ (− = no haemolysis; + = lysis only underneath the colonies; ++ = a small zone of lysis around the colonies; +++ = a large zone of lysis).

The α-haemolytic activity of a strain was defined as the highest dilution of the crude α-haemolytic supernate that showed a haemoglobin release of at least 25% of the maximal haemoglobin release from the erythrocyte suspensions (MHR25).

**Elimination of haemolysin production.** Experiments to eliminate haemolysis from *E. coli* were done according to the method described by Mitchell and Kenworthy (1977). Bacteria were grown overnight in Nutrient Broth (Oxoid) at 37°C, diluted to a density of 10⁷ bacteria/ml, and 0.1 ml of this suspension was added to 10 ml of nutrient broth containing actinomycin-D (40 μg/ml or more) or rifampicin (3 μg/ml or more). Cultures were sampled after 24 h and, if necessary, after 48 h; they were diluted in PBS and plated on to washed-blood agar to yield separate colonies. When colonies with altered haemolytic activity were not found, a few drops of the culture were transferred to fresh nutrient broth with the agent under test, and the procedure was repeated. For each strain actinomycin-D was used first, up to a concentration of 200 μg/ml. When elimination of actinomycin-D production was not observed, rifampicin was subsequently used, up to a maximum concentration of 30 μg/ml. Colonies with altered haemolysis were tested for growth rate, biotype, serotype, antibiotic-sensitivity pattern, colicine production and haemagglutination pattern. Growth rates in nutrient broth were tested by following the optical density at 650 nm. Biotypes were determined by the API 20E system (API system S.A., Montalieu Vercieu, France). Serotypes (O and K) were determined by P. A. M. Guinée and W. H. Jansen at the National Institute of Public Health, Bilthoven, The Netherlands. The antibiotic-sensitivity patterns with seven antibiotics were determined by the agar-diffusion technique on antibiotic-sensitivity medium with paper disks (AB Biodisk, Solna, Sweden). Colicine production was tested against *E. coli* Row strain PC 1408, which is sensitive to all known colicines and originated from Frédéricq (Phabagen Collection, Laboratory for Microbiology, Utrecht, The Netherlands). Colonies were killed with chloroform, and overlaid...
HAEMOLYSIS BY E. COLI

with soft nutrient agar (0.6% (w/v) agar) containing a 50-fold dilution of an overnight culture of indicator strain PC1408. Inhibition zones were read after overnight incubation at 37°C. To test the haemagglutination pattern, bacteria grown overnight in nutrient broth with gentle agitation and on washed-blood agar plates were harvested and resuspended in PBS to a concentration of 10⁶ bacteria/ml. Serial twofold dilutions were made in 100-μl volumes of PBS, and 100 μl of 0.5% guinea-pig or human group-A erythrocytes, washed in PBS, was added to each dilution. The mannose sensitivity of the haemagglutination was tested by addition of 1% D-mannose to the erythrocyte suspensions. Agglutination was read after incubation for 2 h at 0°C.

Virulence test. The virulence of the strains was tested as described by van den Bosch et al. (1979). Approximately 2.5 × 10⁶ log-phase cells of the test strains were injected intravenously into mice, and the viable counts in the mouse kidney were measured at different intervals up to 8 h after injection. Avirulent group-I strains show low counts throughout the experiment; mouse nephropathogenic group-II strains show high counts in the kidney after an initial decline; and the most virulent group-III strains show high counts immediately after injection which remain high. Two mice were included in each assay to determine whether they survived the inoculum.

RESULTS

Haemolysin production and virulence

Fifty-five urinary strains of E. coli were tested for haemolysin production on washed-blood agar and for virulence. The distribution of haemolytic and nonhaemolytic strains amongst the three virulence groups is shown in table I. Virulent group-II and group-III strains were haemolytic more often than avirulent group-I strains (χ² test on a 2 × 3 table, p = 0.002). All haemolytic strains produced α haemolysin. The relationship between α-haemolytic activity and virulence is shown in fig. 1. Systematic differences in α-haemolytic activity could not be shown between haemolytic strains from different virulence groups (χ² test on mean scores, p = 0.52).

Table II shows the time to death for the mice challenged with haemolytic or nonhaemolytic strains from the different virulence groups. Within each virulence group, the haemolytic strains killed the mice more rapidly than the nonhaemolytic strains. Furthermore, we observed that two-thirds of the haemolytic virulent strains (groups II and III) caused macroscopic haemoglobinuria in the mice within 8 h after injection; this was not observed with nonhaemolytic strains nor with the four haemolytic but avirulent group-I strains. Amongst the haemolytic strains, there was no relationship between

<table>
<thead>
<tr>
<th>Table I</th>
<th>Distribution of haemolytic and nonhaemolytic strains of E. coli amongst virulence groups I, II and III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemolytic activity</td>
<td>Number of strains in virulence group*</td>
</tr>
<tr>
<td></td>
<td>I</td>
</tr>
<tr>
<td>Haemolytic</td>
<td>4</td>
</tr>
<tr>
<td>Nonhaemolytic</td>
<td>20</td>
</tr>
</tbody>
</table>

* Group I = avirulent strains; group II = mouse-nephropathogenic strains; group III = virulent strains.
**FIG. 1.**—α-Haemolytic activity of haemolytic strains of *E. coli* belonging to the three virulence groups. MHR25 = 25% of maximal haemoglobin release; see *Methods*.

α-haemolytic activity and the time to death, or between α-haemolytic activity and haemoglobinuria.

**Elimination of haemolysin production**

The results of the elimination experiments on haemolytic strains varied between the strains tested. A reduction of haemolysin production was achieved in most strains. However, the agent and the concentration of agent required differed between strains; with actinomycin-D, concentrations from 40
HAEMOLYSIS BY E. COLI

TABLE II
Time to death for mice challenged with haemolytic and nonhaemolytic E. coli strains of different virulence groups

<table>
<thead>
<tr>
<th>Virulence group*</th>
<th>Haemolytic activity</th>
<th>Number of strains causing death during the stated period after intravenous injection</th>
<th>Number of avirulent strains†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&lt;8h</td>
<td>8h &lt; 1d</td>
</tr>
<tr>
<td>I</td>
<td>Nonhaemolytic</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td></td>
<td>Haemolytic</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>II</td>
<td>Nonhaemolytic</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td></td>
<td>Haemolytic</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>III</td>
<td>Nonhaemolytic</td>
<td>9</td>
<td>...</td>
</tr>
<tr>
<td></td>
<td>Haemolytic</td>
<td>...</td>
<td>...</td>
</tr>
</tbody>
</table>

h = Hours; d = day(s).
* See footnote to table I.
† Test mice alive after 14 days.

Effect of altered haemolysin production on virulence

Virulence tests were done on variants in which altered haemolysin production was the only change observed. For all but one strain, a control isolate treated with the agent but with no change in haemolysin production or other character, was also tested. All variants were stable in vitro and after passage through the mouse.

Fig. 3 shows an example of the effect of changing the haemolytic activity on the virulence of a mouse-nephropathogenic group-II strain (AD109). The behaviour in the mouse kidney of the wild-type haemolytic strain and of the control strain, treated with the agent but not changed in haemolytic activity, were similar. However, the variant with reduced haemolytic activity and the nonhaemolytic variant behaved as avirulent group-I strains. The effect of
reducing or abolishing the haemolysin production on the virulence of five out of another six group-II strains was similar (table III). The only exception was strain AD336: the nonhaemolytic variant behaved in the mouse kidney as the haemolytic parent strain. In addition to the change of most group-II strains into group I, the time to death of the mice challenged with the variants with reduced or abolished haemolytic activity was longer than the time with the haemolytic wild-type and control strains. Furthermore, the haemoglobinuria seen in mice challenged with some haemolytic wild-type and control strains was not observed after injection of variants with reduced haemolytic activity or nonhaemolytic variants.

Fig. 4 shows an example of the effect of reduced haemolysin production on the virulence of a group-III strain (AD121). The behaviour in the mouse kidney of the wild-type haemolytic strain, the haemolytic control isolate, the variant with reduced haemolytic activity and the nonhaemolytic variant, was similar. The results obtained with three other group-III strains were the same.
FIG. 2.—Different types of altered haemolysis on blood agar: c = unchanged haemolysis (control); a = colony showing reduced haemolytic activity; b = nonhaemolytic colony.
### Table III

**Effect of reduction and elimination of haemolysin production on the virulence of mouse-nephropathogenic group-II strains**

<table>
<thead>
<tr>
<th>E. coli strain no. and variant*</th>
<th>Haemolysis on blood agar†</th>
<th>α-Haemolytic activity (dilution)‡</th>
<th>Serotype</th>
<th>Virulence group</th>
<th>Time to death§</th>
<th>Haemoglobinuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD109</td>
<td>++</td>
<td>32</td>
<td>O75:K^-</td>
<td>II</td>
<td>&lt;8h</td>
<td>+</td>
</tr>
<tr>
<td>AD109a</td>
<td>++</td>
<td>16</td>
<td>O75:K^-</td>
<td>I</td>
<td>4d-&lt;14d</td>
<td>-</td>
</tr>
<tr>
<td>AD109b</td>
<td>—</td>
<td>Absent</td>
<td>O75:K^-</td>
<td>I</td>
<td>4d-&lt;14d</td>
<td>-</td>
</tr>
<tr>
<td>AD109c</td>
<td>++</td>
<td>64</td>
<td>O75:K^-</td>
<td>II</td>
<td>&lt;8h</td>
<td>+</td>
</tr>
<tr>
<td>AD110</td>
<td>++</td>
<td>64</td>
<td>O6:K2</td>
<td>II</td>
<td>8h-&lt;1d</td>
<td>-</td>
</tr>
<tr>
<td>AD110a</td>
<td>++</td>
<td>4</td>
<td>O6:K2</td>
<td>I</td>
<td>avirulent</td>
<td>-</td>
</tr>
<tr>
<td>AD110b</td>
<td>—</td>
<td>Absent</td>
<td>O6:K2</td>
<td>I</td>
<td>avirulent</td>
<td>-</td>
</tr>
<tr>
<td>AD110c</td>
<td>++</td>
<td>32</td>
<td>O6:K2</td>
<td>II</td>
<td>8h-&lt;1d</td>
<td>-</td>
</tr>
<tr>
<td>AD111</td>
<td>++</td>
<td>16</td>
<td>O6:K2</td>
<td>II</td>
<td>1d-&lt;4d</td>
<td>+</td>
</tr>
<tr>
<td>AD111a</td>
<td>+</td>
<td>Absent</td>
<td>O6:K2</td>
<td>I</td>
<td>avirulent</td>
<td>-</td>
</tr>
<tr>
<td>AD111c</td>
<td>++</td>
<td>16</td>
<td>O6:K2</td>
<td>II</td>
<td>1d-&lt;4d</td>
<td>-</td>
</tr>
<tr>
<td>AD113</td>
<td>++</td>
<td>128</td>
<td>O4:K3</td>
<td>II</td>
<td>1d-&lt;4d</td>
<td>-</td>
</tr>
<tr>
<td>AD113a</td>
<td>++</td>
<td>8</td>
<td>O4:K3</td>
<td>I</td>
<td>avirulent</td>
<td>-</td>
</tr>
<tr>
<td>AD113c</td>
<td>++</td>
<td>128</td>
<td>O4:K3</td>
<td>II</td>
<td>1d-&lt;4d</td>
<td>-</td>
</tr>
<tr>
<td>AD27</td>
<td>++</td>
<td>256</td>
<td>O139:K82</td>
<td>II</td>
<td>&lt;8h</td>
<td>+</td>
</tr>
<tr>
<td>AD27b</td>
<td>—</td>
<td>Absent</td>
<td>O139:K82</td>
<td>I</td>
<td>avirulent</td>
<td>-</td>
</tr>
<tr>
<td>AD310</td>
<td>++</td>
<td>128</td>
<td>O6:K2</td>
<td>II</td>
<td>8h-&lt;1d</td>
<td>+</td>
</tr>
<tr>
<td>AD310a</td>
<td>++</td>
<td>16</td>
<td>O6:K2</td>
<td>I</td>
<td>4d-&lt;14d</td>
<td>-</td>
</tr>
<tr>
<td>AD310b</td>
<td>—</td>
<td>Absent</td>
<td>O6:K2</td>
<td>I</td>
<td>4d-&lt;14d</td>
<td>-</td>
</tr>
<tr>
<td>AD310c</td>
<td>++</td>
<td>128</td>
<td>O6:K2</td>
<td>II</td>
<td>8h-&lt;1d</td>
<td>+</td>
</tr>
<tr>
<td>AD336</td>
<td>++</td>
<td>16</td>
<td>O8:K25</td>
<td>II</td>
<td>1d-&lt;4d</td>
<td>-</td>
</tr>
<tr>
<td>AD336b</td>
<td>—</td>
<td>Absent</td>
<td>O8:K25</td>
<td>II</td>
<td>4d-&lt;14d</td>
<td>-</td>
</tr>
<tr>
<td>AD336c</td>
<td>++</td>
<td>16</td>
<td>O8:K25</td>
<td>II</td>
<td>1d-&lt;4d</td>
<td>-</td>
</tr>
</tbody>
</table>

* a = Variant with reduced haemolytic activity; b = nonhaemolytic variant; c = control strain treated with curing agent but not changed in haemolytic activity. All variant strains were “cured” with actinomycin-D, except AD113 which was “cured” with rifampicin.

† See Methods.
‡ See footnote to table I.
§ See footnote to table II.

Reducing or abolishing the haemolysin production of group-III strains produced a small decrease in killing time for the mice (fig. 4 and table IV). Furthermore, three of the four haemolytic group-III strains gave rise to haemoglobinuria in the mice, whereas most of the variants with reduced haemolysin production did not.

In addition to the change in haemolytic activity, some strains lost their K antigen after treatment with actinomycin-D or rifampicin. We isolated variants with reduced haemolytic activity from the group-III strains AD117 and AD121, both O6:K23, that no longer produced K antigen. These K^- variants behaved as avirulent group-I strains. From strain AD118, also O6:K23, we isolated a variant with reduced haemolytic activity that we presumed had a smaller amount of K23 antigen because the unheated culture was agglutinated with O6 antiserum but still reacted with K23 antiserum. This variant behaved as an avirulent group-I strain.
Fig. 4.—Effect of reduction and elimination of haemolysin production on the virulence of group-III strain AD121 for the mouse kidney. w.t. = Wild type haemolytic strain; a = variant with reduced haemolytic activity; b = nonhaemolytic variant; c = control strain with no change in haemolysis.

**Table IV**

*Effect of reduction and elimination of haemolysin production on the virulence of group-III strains*

<table>
<thead>
<tr>
<th>E. coli strain no. and variant*</th>
<th>Haemolysis (dilution)†</th>
<th>α-Haemolytic activity (dilution)‡</th>
<th>Serotype</th>
<th>Virulence group‡</th>
<th>Time to death§</th>
<th>Haemoglobinuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD117</td>
<td>+++</td>
<td>32</td>
<td>O6:K23</td>
<td>III</td>
<td>&lt; 8h</td>
<td>+</td>
</tr>
<tr>
<td>AD117a</td>
<td>+</td>
<td>8</td>
<td>O6:K23</td>
<td>III</td>
<td>&lt; 8h</td>
<td>+</td>
</tr>
<tr>
<td>AD117b</td>
<td>Absent</td>
<td></td>
<td>O6:K23</td>
<td>III</td>
<td>8h–&lt; 1d</td>
<td>–</td>
</tr>
<tr>
<td>AD117c</td>
<td>+++</td>
<td>32</td>
<td>O6:K23</td>
<td>III</td>
<td>&lt; 8h</td>
<td>+</td>
</tr>
<tr>
<td>AD118</td>
<td>+++</td>
<td>32</td>
<td>O6:K23</td>
<td>III</td>
<td>&lt; 8h</td>
<td>+</td>
</tr>
<tr>
<td>AD118b</td>
<td>Absent</td>
<td></td>
<td>O6:K23</td>
<td>III</td>
<td>8h–&lt; 1d</td>
<td>–</td>
</tr>
<tr>
<td>AD118c</td>
<td>+++</td>
<td>32</td>
<td>O6:K23</td>
<td>III</td>
<td>&lt; 8h</td>
<td>+</td>
</tr>
<tr>
<td>AD119</td>
<td>+++</td>
<td>256</td>
<td>O18:K2</td>
<td>III</td>
<td>&lt; 8h</td>
<td>–</td>
</tr>
<tr>
<td>AD119b</td>
<td>Absent</td>
<td></td>
<td>O18:K2</td>
<td>III</td>
<td>8h–&lt; 1d</td>
<td>–</td>
</tr>
<tr>
<td>AD119c</td>
<td>+++</td>
<td>256</td>
<td>O18:K2</td>
<td>III</td>
<td>&lt; 8h</td>
<td>–</td>
</tr>
<tr>
<td>AD121</td>
<td>+++</td>
<td>16</td>
<td>O6:K23</td>
<td>III</td>
<td>&lt; 8h</td>
<td>+</td>
</tr>
<tr>
<td>AD121a</td>
<td>+</td>
<td>8</td>
<td>O6:K23</td>
<td>III</td>
<td>8h–&lt; 1d</td>
<td>–</td>
</tr>
<tr>
<td>AD121b</td>
<td>Absent</td>
<td></td>
<td>O6:K23</td>
<td>III</td>
<td>&lt; 8h</td>
<td>–</td>
</tr>
<tr>
<td>AD121C</td>
<td>+++</td>
<td>16</td>
<td>O6:K23</td>
<td>III</td>
<td>&lt; 8h</td>
<td>+</td>
</tr>
</tbody>
</table>

* See footnote (*) to table III.  † See footnote to table I.  ‡ See Methods.  § See footnote to table II.
DISCUSSION

The present results lead us to conclude that haemolysin production in urinary strains of *E. coli* is a virulence factor of importance for some virulent strains. In all strains, haemolysis contributed to the toxicity for mice, but only in most of the mouse nephropathogenic group-II strains did it seem to be a decisive factor for virulence. Previously we have shown that group-II strains are frequently found among *E. coli* strains isolated from the urine of patients with acute pyelonephritis or asymptomatic bacteriuria, less often among isolates from acute cystitis and not among faecal isolates (van den Bosch *et al.*, 1980a, 1981). Therefore, we consider that haemolysis by *E. coli* plays a role in the pathogenesis of upper urinary tract infections, but that other virulence factors must be involved also. Six out of 17 group-II strains were nonhaemolytic, and the virulence of one of the seven haemolytic group-II strains was not affected by elimination of the haemolysin production. Furthermore, four avirulent group-I strains were haemolytic. Haemolysis did not seem to be an important virulence factor for the more virulent group-III strains found amongst acute pyelonephritis, acute cystitis and faecal isolates (van den Bosch *et al.*, 1980a, 1981). However, the present study indicates that the K23 antigen may be a virulence factor in some group-III strains.

Our present finding that α-haemolysin production by urinary strains of *E. coli* contributed to their toxicity for mice, but seemed to be a decisive virulence factor only in some nephropathogenic group-II strains is consistent with other investigations. There is epidemiological evidence that haemolysin production is a virulence factor in the pathogenesis of urinary-tract infection (Dudgeon *et al.*, 1921, 1922; Cooke and Ewins, 1975; Minshew *et al.*, 1978a and b), and Fried *et al.* (1971) found an association between haemolysin production by *E. coli* and the ability to produce pyelonephritis in mice and rats after intravenous injection. Several studies have shown the association of α haemolysin with general toxicity and necrotoxicity for various animals, and with cytotoxicity for various cells (Smith, 1963; Smith and Halls, 1967; Chaturvedi *et al.*, 1969; Smith and Linggood, 1971; Cooke and Ewins, 1975; Kétyi *et al.*, 1978; Minshew *et al.*, 1978a and b; Emödy *et al.*, 1979). However, Rennie and Arbuthnott (1974) did not find that purified α haemolysin was toxic for mice and rabbits after intravenous injection, in contrast with the results obtained with crude α-haemolysin preparations (Smith, 1963; Smith and Halls, 1967). This indicates that another toxin, closely correlated with α haemolysin, might be involved.

In the present study we found that haemolysin production by *E. coli* was easily eliminated in most cases by treatment with actinomycin-D or rifampicin which suggests that the haemolysin production was plasmid mediated. Several studies have indicated that haemolysin production in most haemolytic strains of *E. coli* is mediated by a *Hly* plasmid (Smith and Halls, 1967; Goebel and Schrempf, 1971; Smith and Linggood, 1971; Goebel *et al.*, 1974). However, Hull *et al.* (1980) recently found evidence that in one *E. coli* strain haemolysin production is chromosomal, and Minshew *et al.* (1978a) suggested that the
haemolysin of most extraintestinal strains is not plasmid mediated. We have not shown that our strains were cured of a Hly plasmid, although the frequencies of elimination suggest this.

Treatment of haemolytic strains with an agent of known curing activity (Mitchell and Kenworthy, 1977) frequently resulted in the appearance of two types of colony with altered haemolysin production: a nonhaemolytic variant and a variant with reduced haemolytic activity (fig. 2). Hull et al. (1980) also found these two variants after treatment of one strain with a chemical mutagen. We cannot explain this phenomenon because all but one of the variants with reduced haemolytic activity had not lost the ability to produce either α or β haemolysin; neither can we explain the contradiction between our finding that variants of group-II strains that showed reduced α-haemolytic activity behaved as avirulent group-I strains, and our finding, also described by Smith and Linggood (1971), that α-haemolytic activity did not seem to affect the virulence of wild-type haemolytic strains. It is possible that an E. coli strain could produce several different α-haemolysins at the same time, all of which may not be relevant to virulence.

We are very grateful to P. A. M. Guinee and W. H. Jansen, National Institute of Public Health, Bilthoven, The Netherlands, for checking the serotypes of our strains. The skilled technical assistance of W. F. Schouten with the animal experiments is acknowledged, and we thank P. A. R. Koopman, Department of Medical Statistics, Free University, for statistical analysis and helpful discussions.

REFERENCES


HAEMOLYSIS BY E. COLI


